Market Closed -
Nasdaq
04:30:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
3.2
USD
|
+1.91%
|
|
+6.31%
|
+44.14%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
104.7
|
6.34
|
2.349
|
Enterprise Value (EV)
1 |
22.88
|
-27.28
|
-0.7846
|
P/E ratio
|
-1.81
x
|
-0.09
x
|
-0.07
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
EV / EBITDA
|
-0.44
x
|
0.44
x
|
0.03
x
|
EV / FCF
|
-755,087
x
|
922,731
x
|
43,831
x
|
FCF Yield
|
-0%
|
0%
|
0%
|
Price to Book
|
1.26
x
|
0.2
x
|
0.67
x
|
Nbr of stocks (in thousands)
|
908
|
1,043
|
1,058
|
Reference price
2 |
115.2
|
6.078
|
2.220
|
Announcement Date
|
3/9/22
|
3/28/23
|
4/16/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-13.04
|
-20.45
|
-27.23
|
-52.39
|
-62.09
|
-28.16
|
EBIT
1 |
-13.24
|
-20.89
|
-27.85
|
-53.26
|
-63.08
|
-29.18
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.83
|
-20.55
|
-29.87
|
-50.9
|
-62.51
|
-32.34
|
Net income
1 |
-12.83
|
-20.55
|
-29.87
|
-50.9
|
-62.51
|
-32.34
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-332.0
|
-467.7
|
-660.4
|
-63.51
|
-64.95
|
-30.82
|
Free Cash Flow
|
-
|
-12.96
|
-15.92
|
-30.3
|
-29.56
|
-17.9
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/19/21
|
1/19/21
|
3/31/21
|
3/9/22
|
3/28/23
|
4/16/24
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.53
|
-15.05
|
-15.93
|
-14.86
|
-17.25
|
-9.825
|
-7.785
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.53
|
-15.02
|
-15.86
|
-14.73
|
-16.89
|
-9.565
|
-7.566
|
Net income
1 |
-15.53
|
-15.02
|
-15.86
|
-14.73
|
-16.89
|
-9.565
|
-7.566
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-17.25
|
-16.50
|
-17.25
|
-15.00
|
-16.25
|
-9.250
|
-7.250
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/22
|
5/12/22
|
8/15/22
|
11/14/22
|
3/28/23
|
5/15/23
|
8/10/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
14.9
|
-
|
-
|
-
|
Net Cash position
1 |
12.1
|
10.1
|
-
|
81.8
|
33.6
|
3.13
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.5487
x
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-13
|
-15.9
|
-30.3
|
-29.6
|
-17.9
|
ROE (net income / shareholders' equity)
|
-
|
-192%
|
1,161%
|
-150%
|
-108%
|
-181%
|
ROA (Net income/ Total Assets)
|
-
|
-93.7%
|
-139%
|
-65.1%
|
-58.8%
|
-70.6%
|
Assets
1 |
-
|
21.93
|
21.46
|
78.25
|
106.3
|
45.8
|
Book Value Per Share
2 |
-540.0
|
-857.0
|
-1,380
|
91.70
|
31.00
|
3.290
|
Cash Flow per Share
2 |
9.490
|
182.0
|
100.0
|
33.20
|
33.20
|
3.000
|
Capex
1 |
0.94
|
1.25
|
0.86
|
2.35
|
1.26
|
0.05
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/19/21
|
1/19/21
|
3/31/21
|
3/9/22
|
3/28/23
|
4/16/24
|
|
1st Jan change
|
Capi.
|
---|
| +44.14% | 4.39M | | +19.33% | 125B | | +13.95% | 108B | | -3.53% | 24.57B | | +3.49% | 22.82B | | -10.21% | 18.19B | | -41.48% | 16.54B | | -12.62% | 16.5B | | +0.99% | 13.39B | | +21.79% | 11.1B |
Bio Therapeutic Drugs
|